5 AMINOIMIDAZOLE 4 CARBOXAMIDE IN PSORIASIS PATIENTS URINE TAKING METHOTREXATE

5 氨基咪唑 4 甲酰胺在银屑病患者尿液中服用甲氨蝶呤

• 批准号: 6244013
• 负责人: SARAH LUISE MORGAN
• 金额: $ 2.46万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-10 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244013
• 关键词: adenosine; clinical research; cytotoxicity; deoxyadenosines; dietary supplements; drug adverse effect; folate; high performance liquid chromatography; human subject; human therapy evaluation; imidazole carboxamide; methotrexate; nutrition related tag; psoriasis; urinalysis

This protocol was conducted to demonstrate whether a folic acid supplement (7 mg or 38.5 mg/week) would reduce methotrexate toxicity in patients with psoriasis while preserving the efficacy of the drug. In addition, we attempted to demonstrate that urinary levels of aminoimidazole carboxamide (AIDA), adenosine (Ado), and dexoyadenosine (dAdo) are elevated in methotrexate-treated patients with psoriasis compared to controls. AICA, Ado, and dAdo are known to be immunotoxic substances and they may be the link between methotrexate therapy, immunosuppression and efficacy in psoriasis therapy. This study has been concluded and we are currently analyzing data.

本方案旨在证明叶酸是否 补充（7 mg或38.5 mg/周）将降低甲氨蝶呤的毒性， 银屑病患者同时保留药物的疗效。 在 此外，我们试图证明尿中的 氨基咪唑甲酰胺（AIDA）、腺苷（Ado）和脱氧腺苷 甲氨蝶呤治疗的银屑病患者中， 与对照相比。 已知AICA、Ado和dAdo具有免疫毒性 物质，它们可能是甲氨蝶呤治疗， 银屑病治疗中免疫抑制和功效。本研究已 目前，我们正在分析数据。